Bao KKH, Wong ICK, Tse G, Zhang Q. Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis. Cardiooncology. 2022 Mar 17;8(1):5. ...
2. Wang Y, Zhou S, Yang F, et al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol. 2019, 5(7): 1008-1019. doi: 10.1001/jamaoncol.2019.0393....
[17]FENG Z, RONG P, WANG W. Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors administered alone or in combination with anti-VEGF agents in advanced hepatocellular carcinoma[J]. Gut, 2020, 69(10): 1904-1906. DOI: 10.1136/gutjnl-2019-320116 [18]KUDO M. Immuno-oncol...
为了更好地了解这些药物在特定患者群体中的疗效,未来需要进行更多的前瞻性研究,并对不同生物标志物下的疗效进行更深入的探索和评估。 参考文献:Akers KG, et al. Clinical Outcomes of PD-1/PD-L1 Inhibitors Among Patients With...
PD-1/PD-L1等免疫检查点蛋白的发现代表了肿瘤免疫治疗领域的重大突破,靶向这些免疫检查点蛋白的人源化单克隆抗体即免疫检查点抑制剂(Immune Checkpoint Inhibitors,ICIs)已成功用于包括肺癌、食管癌、胃癌、尿路上皮癌、肝癌、结直肠癌、乳腺癌、经典型霍奇金淋巴瘤及恶性黑色素细胞瘤等肿瘤的治疗之中,以PD-1/PD-...
A systematic review and meta-analysis of PD-1/PD-L1 inhibitors inspecific patient subgroups with advanced gastro-oesophageal junction and gastricadenocarcinoma[J]. Crit Rev Oncol Hematol. 2020,11(157): 103173. 2. Kim ST, Cristescu R.,Bass AJ., et al. Comprehensive molecular characterization ...
免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)为代表的免疫疗法通过激活患者自身 T 淋巴细胞的抗肿瘤免疫功能,发挥杀灭肿瘤细胞的作用,在临床上已被广泛使用。 ICIs 作为针对细胞毒性 T 淋巴细胞相关抗原 4(cytotoxic T-lymphocyte-associated protein 4,CTLA-4)和程序性死亡蛋白 1(programmed death 1,PD-1)...
[17]FENG Z, RONG P, WANG W. Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors administered alone or in combination with anti-VEGF agents in advanced hepatocellular carcinoma[J]. Gut, 2020, 69(10): 1904-1906. DOI: 10.1136/gutjnl-2019-320116 ...
[3]. Abdin SM, et al. Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors. Cancers (Basel). 2018 Jan 25;10(2):32. [4]. Chen X, et al. FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer ...
让我们拭目以待。 参考资料: 1. Insight 数据库; 2. Progress in the application of PD-1 /PD-L1 inhibitors in neoadjuvant chemotherapy,Chinese Journal of New Drugs,2020; 3. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.New Eng J Med, 2018....